<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter)</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_left border_right_thick" colspan="2">Inhibitors of P-gp</td> <td class="subtitle1_left">Inducers of P-gp</td> </tr> <tr> <td> <ul> <li>Abrocitinib</li> <li>Adagrasib</li> <li>Amiodarone</li> <li>Azithromycin (systemic)</li> <li>Cannabidiol and cannabidiol-containing coformulations</li> <li>Capmatinib</li> <li>Carvedilol</li> <li>Clarithromycin</li> <li>Cobicistat and cobicistat-containing coformulations</li> <li>Cyclosporine (systemic)</li> <li>Daclatasvir</li> <li>Daridorexant</li> <li>Diosmin (a plant flavonoid sold as dietary supplement)</li> <li>Dronedarone</li> <li>Elagolix</li> <li>Elagolix-estradiol-norethindrone</li> <li>Eliglustat</li> <li>Elexacaftor-tezacaftor-ivacaftor</li> <li>Enzalutamide</li> <li>Erythromycin (systemic)</li> <li>Flibanserin</li> <li>Fostamatinib</li> <li>Glecaprevir-pibrentasvir</li> <li>Isavuconazole (isavuconazonium sulfate)</li> <li>Itraconazole</li> <li>Ivacaftor</li> <li>Ketoconazole (systemic)</li> </ul> </td> <td class="border_right_thick"> <ul> <li>Lapatinib</li> <li>Ledipasvir</li> <li>Levoketoconazole</li> <li>Mifepristone<sup>*</sup></li> <li>Neratinib</li> <li>Nirmatrelvir-ritonavir</li> <li>Ombitasvir-paritaprevir-ritonavir (Technivie)<sup>¶</sup></li> <li>Osimertinib</li> <li>Pirtobrutinib</li> <li>Posaconazole</li> <li>Propafenone</li> <li>Quinidine</li> <li>Quinine</li> <li>Ranolazine</li> <li>Ritonavir and ritonavir-containing coformulations<sup>¶</sup></li> <li>Rolapitant</li> <li>Selpercatinib</li> <li>Simeprevir</li> <li>Sotagliflozin</li> <li>Sotorasib<sup>Δ</sup></li> <li>Tamoxifen<sup>Δ</sup></li> <li>Tepotinib</li> <li>Tezacaftor-ivacaftor</li> <li>Ticagrelor<sup>Δ</sup></li> <li>Tucatinib</li> <li>Velpatasvir</li> <li>Vemurafenib</li> <li>Verapamil</li> <li>Voclosporin</li> </ul> </td> <td> <ul> <li>Apalutamide</li> <li>Carbamazepine</li> <li>Fosphenytoin</li> <li>Green tea (<em>Camellia sinensis</em>)</li> <li>Lorlatinib</li> <li>Phenytoin</li> <li>Rifampin (rifampicin)</li> <li>St. John's wort</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Inhibitors of the P-gp drug efflux pump (also known as P-gp multidrug resistance transporter) listed above may <strong>increase</strong> serum concentrations of drugs that are substrates of P-gp, whereas inducers of P-gp drug efflux may <strong>decrease</strong> serum concentrations of substrates of P-gp.</li>
<li>Examples of drugs that are substrates of P-gp efflux pump include: Apixaban, colchicine, cyclosporine, dabigatran, digoxin, edoxaban, rivaroxaban, and tacrolimus.</li>
<li>The degree of effect on P-gp substrate serum concentration may be altered by dose and timing of orally administered P-gp inhibitor or inducer.</li>
<li>These classifications are based upon US FDA <span class="nowrap_whitespace">guidance.<sup>[1,2]</sup></span> Other sources may use a different classification system resulting in some agents being classified differently.</li>
<li>Specific drug interaction effects may be determined by using the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included with UpToDate. Refer to UpToDate clinical topics on specific agents and conditions for further details.</li>
</ul></div><div class="graphic_footnotes"><p>P-gp: P-glycoprotein; US FDA: US Food and Drug Administration.</p>
<p>* Mifepristone is a significant inhibitor of P-gp when used chronically (eg, for hyperglycemia in patients with Cushing syndrome); not in single-dose use.</p>
<p>¶ The combination of ombitasvir-paritaprevir-ritonavir plus dasabuvir (Viekira Pak) is not a significant inhibitor of P-gp efflux <span class="nowrap_whitespace">pump.<sup>[3]</sup></span></p>
Δ Minor clinical effect or supportive data are limited to in vitro effects (ie, clinical effect is unknown).</div><div class="graphic_reference"><p>Data from: Lexicomp Online (Lexi-Interact). Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p>
References:
<ol>
<li>US Food and Drug Administration. Clinical drug interaction studies – Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available at: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a> (Accessed on June 5, 2020).</li>
<li>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: <a href="https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers" target="_blank">FDA.gov website</a>.</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20.</li>
</ol></div><div id="graphicVersion">Graphic 73326 Version 83.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
